Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

A Novel Synthetic Short-Chain Polyphosphate (polyP) Complexed with Silica Nanoparticle (SNP) Improves Hemostatic Outcomes in Severe Swine and Rat Injury Models

Damien Kudela, Kyle Ploense, Genmin Lu, Charles Pollack, Andrea Ashford-Hicks, James H. Morrissey

Blood (2024) 144 (Supplement 1): 3964.

https://doi.org/10.1182/blood-2024-208313

Published: 2024

Journal Articles

Analytical Performance of Modified Anti-FXa Assays for Andexanet Alfa-Containing Plasma Samples on the ACL TOP/TOP 50 Coagulation Analyzers

Anuja Khan, PhD, Krisjela Shishko, BS, Ryan Marett, BS, Sam Arcidiacono, BS, MT(ASCP), Vy Nguyen, BS, Genmin Lu, Khanh Bui, BS, Pamela B. Conley, PhD, Anne Winkler, MD

Blood (2020) 136 (Supplement 1): 5.

https://doi.org/10.1182/blood-2020-141006

Published: 2020

Journal Articles

Validation of a Modified Anti-FXa Assay on STA-Compact Analyzer for Measuring FXa Inhibitor Levels in the Presence of Andexanet Alfa

Juan Cardenas, PhD, Jayaprakash Kotha, PhD MBBS, Genmin Lu, Pamela B. Conley, PhD, Matthieu Bourdin, Tristan Herve, Lisa K. Jennings, PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-140988

Published: 2020

Journal Articles

Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors

Michiel Coppens, MD, Lizhen Xu, PhD, Roisin Bavalia, MD, Saskia Middeldorp, MD PhD, Peter Verhamme, MD PhD, John W. Eikelboom, MBBS, MSc, FRACP, FRCPA, Mark Crowther, MD, Genmin Lu, Patrick Yue, MD, Pamela B. Conley, PhD, Stuart J. Connolly, MD MSc, FRCPC

Blood (2019) 134 (Supplement_1): 711.

https://doi.org/10.1182/blood-2019-124596

Published: 2019

Journal Articles

Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and "Work Around" By PCCs

Genmin Lu, Joyce P. Lin, BS, Khanh Bui, BS, John T. Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2019) 134 (Supplement_1): 713.

https://doi.org/10.1182/blood-2019-124864

Published: 2019

Journal Articles

Modified Anti-FXa Assays for Measuring the Residual Activity of Apixaban and Rivaroxaban in Andexanet Alfa-Containing Samples on the ACL TOP Family ® Coagulation Analyzers

Anuja Khan, PhD, Krisjela Shishko, BS, Sam Arcidiacono, BS, Khanh Bui, BS, Genmin Lu, Pamela B. Conley, PhD, Anne Winkler, MD

Blood (2019) 134 (Supplement_1): 1153.

https://doi.org/10.1182/blood-2019-126254

Published: 2019

Journal Articles

Effect of Andexanet-TFPI Interaction on in Vitro Thrombin Formation and Coagulation Markers in the TF-Pathway

Genmin Lu, Joyce P Lin, BS, John T. Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2017) 130 (Supplement 1): 629.

https://doi.org/10.1182/blood.V130.Suppl_1.629.629

Published: 2017

Journal Articles

Reversal of Betrixaban-Induced Anticoagulation in Healthy Volunteers By Andexanet Alfa

Mark Crowther, MD, Genmin Lu, PhD, Janet M. Leeds, PhD, Joyce Lin, BS, Pamela B. Conley, PhD, Alexander Gold, MD, Stuart J. Connolly, MD, John T. Curnutte, MD PhD

Blood (2016) 128 (22): 143.

https://doi.org/10.1182/blood.V128.22.143.143

Published: 2016

Journal Articles

Andexanet Alfa Reverses Anticoagulation Effects of Enoxaparin and Associated Bleeding in a Rabbit Acute Hemorrhage Model

Polly Pine, PhD, Genmin Lu, PhD, Deogracias Canivel, Pratikhya Pratikhya, BS, MSc, Francis DeGuzman, PhD, Mark Karbarz, PhD, Kentaro Takeda, BS, John Malinowski, PhD, Janet M. Leeds, PhD, John T. Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2016) 128 (22): 1445.

https://doi.org/10.1182/blood.V128.22.1445.1445

Published: 2016

Journal Articles

Andexanet Alfa, a Universal Antidote Under Development for Factor Xa Inhibitors, Reverses Rivaroxaban-Induced Inhibition of Thrombin Generation Initiated By the Intrinsic Coagulation Pathway Independent of TFPI

Genmin Lu, PhD, Joyce Lin, BS, John T. Curnutte, MDPhD, Pamela B. Conley, PhD

Blood (2016) 128 (22): 3831.

https://doi.org/10.1182/blood.V128.22.3831.3831

Published: 2016

Journal Articles

Pharmacokinetic and Pharmacodynamic (PKPD) Modeling to Determine the Andexanet Alfa Dose to Reverse the Anticoagulant Activity of Direct Fxa Inhibitors

Leeds Janet, PhD, Genmin Lu, PhD, John T. Curnutte, MDPhD, Pamela B. Conley, PhD, Jaap W. Mandema, PhD

Blood (2015) 126 (23): 1135.

https://doi.org/10.1182/blood.V126.23.1135.1135

Published: 2015

Journal Articles

Reversal of Heparin-Induced Anticoagulation By Andexanet Alfa, a Universal Antidote for Factor Xa Inhibitors

Genmin Lu, PhD, Joyce Lin, BS, John T. Curnutte, MDPhD, Pamela B. Conley, PhD

Blood (2015) 126 (23): 2329.

https://doi.org/10.1182/blood.V126.23.2329.2329

Published: 2015

Journal Articles

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors

Mark Crowther, MD, Gallia G. Levy, MD PhD, Genmin Lu, PhD, Janet Leeds, PhD, Joyce Lin, BS, Pratikhya Pratikhya, MS, Pamela B. Conley, PhD, Stuart Connolly, MD, John T. Curnutte, MDPhD

Blood (2014) 124 (21): 4269.

https://doi.org/10.1182/blood.V124.21.4269.4269

Published: 2014

Journal Articles

PRT064445 but Not Recombinant Fviia Reverses Rivaroxaban Induced Anticoagulation As Measured by Reduction in Blood Loss in a Rabbit Liver Laceration Model

Stanley J Hollenbach, BS, JD, Genmin Lu, PhD, Siusze Tan, BS, Gail Lee, BS, Hutchaleelaha Athiwat, PhD, Mayuko Inagaki, BS, Uma Sinha, PhD

Blood (2012) 120 (21): 3414.

https://doi.org/10.1182/blood.V120.21.3414.3414

Published: 2012

Journal Articles

Recombinant Antidote for Reversal of Anticoagulation by Factor Xa Inhibitors.

Genmin Lu, PhD, Francis R. DeGuzman, Sanjay Lakhotia, PhD, Stanley J Hollenbach, David R Phillips, PhD, Uma Sinha, PhD

Blood (2008) 112 (11): 983.

https://doi.org/10.1182/blood.V112.11.983.983

Published: 2008

Journal Articles

Active Site-Dependent Substrate Recognition Plays a Primary Role in Determining the Affinity of the Thrombin-Thrombomodulin Complex for Protein C.

Genmin Lu, Ph.D., Sotheavy Chhum, BS, Sriram Krishnaswamy, Ph.D.

Blood (2004) 104 (11): 125.

https://doi.org/10.1182/blood.V104.11.125.125

Published: 2004

NARROW

A Novel Synthetic Short-Chain Polyphosphate (polyP) Complexed with Silica Nanoparticle (SNP) Improves Hemostatic Outcomes in Severe Swine and Rat Injury Models

Analytical Performance of Modified Anti-FXa Assays for Andexanet Alfa-Containing Plasma Samples on the ACL TOP/TOP 50 Coagulation Analyzers

Validation of a Modified Anti-FXa Assay on STA-Compact Analyzer for Measuring FXa Inhibitor Levels in the Presence of Andexanet Alfa

Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors

Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and "Work Around" By PCCs

Modified Anti-FXa Assays for Measuring the Residual Activity of Apixaban and Rivaroxaban in Andexanet Alfa-Containing Samples on the ACL TOP Family ® Coagulation Analyzers

Effect of Andexanet-TFPI Interaction on in Vitro Thrombin Formation and Coagulation Markers in the TF-Pathway

Reversal of Betrixaban-Induced Anticoagulation in Healthy Volunteers By Andexanet Alfa

Andexanet Alfa Reverses Anticoagulation Effects of Enoxaparin and Associated Bleeding in a Rabbit Acute Hemorrhage Model

Andexanet Alfa, a Universal Antidote Under Development for Factor Xa Inhibitors, Reverses Rivaroxaban-Induced Inhibition of Thrombin Generation Initiated By the Intrinsic Coagulation Pathway Independent of TFPI

Pharmacokinetic and Pharmacodynamic (PKPD) Modeling to Determine the Andexanet Alfa Dose to Reverse the Anticoagulant Activity of Direct Fxa Inhibitors

Reversal of Heparin-Induced Anticoagulation By Andexanet Alfa, a Universal Antidote for Factor Xa Inhibitors

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors

PRT064445 but Not Recombinant Fviia Reverses Rivaroxaban Induced Anticoagulation As Measured by Reduction in Blood Loss in a Rabbit Liver Laceration Model

Recombinant Antidote for Reversal of Anticoagulation by Factor Xa Inhibitors.

Active Site-Dependent Substrate Recognition Plays a Primary Role in Determining the Affinity of the Thrombin-Thrombomodulin Complex for Protein C.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only